Lantheus Holdings, Inc. (LNTH) fair value analysis
Nasdaq · Updated 2026-10-19
LNTH price how computed
Forward Fair Value verdict
OvervaluedLNTH is trading at a 10–25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $99.70
- Sector
- Healthcare
- 12-month range
- $50.69–$110.94
- Market cap
- $6.51B
- From 52-week high
- -10.1%
- Shares outstanding
- 65.3M
- Rank in Healthcare by discount to fair value
- #83 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Lantheus Holdings, Inc. is a healthcare company that develops and commercializes diagnostic imaging agents and nuclear medicine products used in medical imaging procedures to help physicians diagnose and treat patients. The company operates globally, with a primary focus on the United States market and international operations serving healthcare providers and patients worldwide.
LNTH currently ranks #83 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $6.51B
- P/E (trailing)
- 18x
- Revenue (TTM)
- $1.56B
- Net margin
- 17.7%
- EPS (TTM)
- $5.51
- Gross margin
- 62.3%
- Debt / equity
- 0.48
- Revenue growth (3-yr avg)
- 7.1%
- Shares outstanding
- 65.3M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Contracting
- 52-week position
- The top quarter of its range
- DCF cross-check
- Fairly Valued
Technicals how computed
- RSI (14-day)
- 29 · oversold
- 50-day average
- $100.37
- 200-day average
- $89.75
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 5 beat, 2 missed
- Quarter by quarter
- 2026-06 ▲ beat (+18.9%)
2026-03 ▲ beat (+18.7%)
2025-12 ▲ beat (+55.3%)
2025-09 ▬ met (0.0%)
2025-06 ▼ miss (-6.5%)
2025-03 ▼ miss (-7.3%)
2024-12 ▲ beat (+3.0%)
2024-09 ▲ beat (+9.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 3 buy · 7 hold · 0 sell (10 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $107
- Target vs last price
- +7.3%
What our data shows for LNTH
- Our model validated 17 trailing price-to-earnings windows for LNTH, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $50.69–$110.94.
- The 14-day relative strength index sits at an oversold 29.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for LNTH
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent LNTH news
TickrTrends' derived news-sentiment signal for LNTH is currently mixed, computed from recent coverage.
- ETFs Are Selling Lantheus (LNTH) on Oct. 19 (gurufocus.com, 2026-10-21)
TickrTrends take: ETF selling activity in Lantheus shares occurred on October 19, which introduces supply pressure into the stock during a period when TickrTrends' valuation model indicates the company trades at elevated levels relative to fundamentals. For investors focused on valuation metrics, this combination of institutional selling flows and an overvalued rating warrants monitoring whether the stock price moves toward more reasonable valuation territory or continues to resist downward pressure despite the sector-wide healthcare positioning. - LNTH Downgraded by Mizuho -- Price Target Lowered to $109 (gurufocus.com, 2026-10-13)
TickrTrends take: Mizuho's downgrade and price target reduction to $109 comes as LNTH is currently assessed as overvalued by TickrTrends metrics, suggesting the analyst action aligns with valuation concerns in the healthcare sector. Investors focused on valuation should monitor whether this downgrade signals broader market reassessment of LNTH's earnings power or competitive positioning relative to its current trading level. The combination of analyst skepticism and overvaluation status indicates the stock may face continued pressure until fundamentals or market expectations adjust. - Avantis U.S. Small Cap Value ETF (AVUV) Buys $4 Million More Sprouts on Oct. 8 (gurufocus.com, 2026-10-12)
TickrTrends take: The Avantis U.S. Small Cap Value ETF increased its position in Sprouts Farmer Market by four million dollars on October 8, indicating continued institutional interest in the company. TickrTrends currently rates LNTH as overvalued within the Healthcare sector, suggesting that investors focused on valuation metrics may want to monitor whether similar value-oriented funds adjust their positions based on changing fundamentals. For valuation-conscious observers, tracking institutional buying patterns in comparable small-cap names can provide context for assessing whether current market prices properly reflect underlying business conditions.
More LNTH news
- CMS Grants Transitional Pass-Through Payment Status to Lantheus (LNTH) PYLARIFY TruVu Injection (gurufocus.com, 2026-09-30)
What people are saying
Follow the LNTH conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — LNTH in the Healthcare sector moved into oversold territory this week as its Relative Strength Index shifted from the neutral zone to oversold levels. The stock's current valuation verdict remains Overvalued despite this technical shift.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is LNTH stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), LNTH is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is LNTH's TickrTrends verdict?
LNTH's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does LNTH compare to other Healthcare stocks?
LNTH ranks #83 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is LNTH overbought or oversold?
LNTH's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does LNTH report earnings next?
LNTH's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does LNTH usually beat earnings estimates?
Over its last 8 reported quarters LNTH beat the consensus estimate 5 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about LNTH?
Of 10 analysts covering LNTH, 3 rate it a buy, 7 a hold and 0 a sell - hold-leaning, with a consensus price target of $107 (+7.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
LNTH vs ABBV · LNTH vs AMGN · LNTH vs AZTA · LNTH vs BIO · LNTH vs CRL